



New Ablatherm[®]-HIFU Site Launched in the United Kingdom

First UK Fixed Revenue-Per-Procedure Service Available at Capio Springfield Hospital

LYON, France, June 20 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announces the introduction of fixed Ablatherm[®]-HIFU services at the Capio Springfield Hospital, United Kingdom.

The Capio Springfield Hospital is the first site in the United Kingdom to use the fixed Ablatherm[®]-HIFU device under EDAP's Revenue-Per-Procedure (RPP) model. This agreement provides the user with dedicated machine availability at volume preferential terms in return for a guaranteed minimum number of procedures performed. Capio Springfield joins a growing list of 120 cutting edge centers offering Ablatherm[®]-HIFU across Europe, and more than 150 worldwide.

Mark Perry, Business Unit Sales Director for the UK at EDAP said: "The launch of Ablatherm[®]-HIFU services in the Capio Springfield Hospital continues the European rollout of Ablatherm[®]-HIFU for prostate cancer in major urology centers. Clearly acceptance and use of HIFU is accelerating in Europe where it is being adopted by many of the top urology centers. We are delighted to add another highly regarded center to our list of clinical and sales champions advancing the cause of Ablatherm[®]-HIFU in Europe."

Jenny Wright, Regional Business Development Manager at the Capio Springfield Hospital added: "We have already completed 15 successful treatments using a mobile Ablatherm[®] system. This new treatment offers real benefits to an increasing number of our patients, and this is why we have now invested in a fixed machine. Compared to other forms of treatment, Ablatherm[®] has fewer side effects because the accuracy means healthy cells are not destroyed. The treatment has been found to be extremely successful for those patients who are not suitable for surgery or whose cancer has returned after radiotherapy and has shown very promising long term results."

"EDAP has spent the last few quarters making substantial investment in the UK to secure broader reimbursement approval and train additional centers," said Marc Oczachowski, CEO of EDAP. "We have built a top sales and marketing team with deep expertise of the UK market using internal and external resources. We are confident of our future as the HIFU treatment preferred by the best uro-oncology centers around the globe."

EDAP is participating in the annual British Association of Urological Surgeons (BAUS) congress held this year in Glasgow, June 18-21. Stephen Brown, Consultant Urological Surgeon at Stepping Hill Hospital, Stockport, will present quality of life results obtained with Ablatherm[®]-HIFU. Brown is one of the pioneering users of Ablatherm[®]-HIFU in the UK.

About Capio

Capio Healthcare UK is the fourth largest provider of independent healthcare services in the UK, with a network of 21 private hospitals, nine NHS Treatment Centres, mental health services, neurological and rehabilitation services and a dedicated eye unit.

More information regarding Capio Springfield Hospital or Capio Healthcare UK can be found online at <http://www.capio.co.uk>

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor

Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at <http://www.edap-tms.com> and <http://www.hifu-planet.com>.

To sign up for alerts please visit <http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0>

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT: EDAP TMS S.A.
Blandine Confort
+33 4 78 26 40 46

Magnolia Investor Relations
Matt Kreps
972 801 4900

SOURCE EDAP TMS S.A.